The European Haemophilia Consortium’s (EHC) periodic review of novel treatments in haemophilia and other bleeding disorders is a newsletter entirely developed by the EHC to help educate EHC National Member Organisations (NMOs) about the rapidly changing landscape of medicinal treatment in rare bleeding disorders. The EHC encourages its NMOs to use and adapt this newsletter to their national needs but takes no responsibility for any changes.
The newsletter covers recent major developments and is divided by different types of disorders for which there is an update to report. The information provided in this newsletter is compiled from multiple sources, including presentations at recent scientific meetings, websites, financial information and by writing directly to pharmaceutical companies. It is then redrafted and presented in easy-to-understand language. This newsletter is updated periodically.
The EHC is grateful for the work and support of the New Products Working Group, which has overseen the content and production of this newsletter. The EHC also wishes to give Declan Noone, EHC President, special thanks for his work on these publications.
The EHC greatly welcomes all treatment developments that may benefit patients in the future. The EHC takes no position on any product type or class reported in this newsletter.
We hope that the information provided herein is useful and are available for any questions.